{"analyses":[{"ciLowerLimit":"0.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.81","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.48"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.6","upperLimit":"31.0","value":"20.0"},{"groupId":"OG001","lowerLimit":"26.6","upperLimit":"68.2","value":"36.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \\[Modified Cheson et al, 2007\\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \\>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEDIAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had an objective response of CR.","reportingStatus":"POSTED","timeFrame":"Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)","title":"Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"months"}